| HOME >> BIOLOGY >> TECHNOLOGY |
With respect to the Company's strategy to expand into new regenerative medicine markets, Osgood noted, "Our newest initiative in this regard is the MarrowXpress(TM), a version of our AutoXpress(TM) Platform targeted to the processing of bone marrow. Our initial focus will be in the use of bone marrow stem cells in the treatment of critical limb ischemia and myocardial ischemia. We are in the process of preparing a 510 (k) submission and CE Mark application."
Separately, the Company announced today the creation of a wholly-owned subsidiary, Vantus(TM) Inc. a veterinary stem cell laboratory services company. Its initial focus will be the harvesting, processing and preservation of equine stem cells for use in treatment of orthopedic injuries in the performance equine market. The Company is also close to completing a formal collaboration with the Center for Equine Health and Stem Cell Regenerative Medicine Group at the University of California, Davis, School of Veterinary Medicine.
"We are making meaningful progress across our entire business, as well as hitting key milestones in our regenerative medicine strategy. We remain optimistic about our long-term prospects and the value of our technology to facilitate our growth initiatives," Osgood said.
For the first six months of fiscal 2008, ThermoGenesis reported revenues of $9.1 million versus $8.0 million in the same period a year ago. Disposable revenues were $4.5 million versus $2.8 million, a 61% increase. The Company reported a net loss of $4.0 million, or $0.07 per share, in the first six months of fiscal 2008, versus a net loss of $3.1 million, or $0.06 per share, in the same period a year ago.
Consistent with prior guidance, the Company said that during the
remainder of fiscal 2008, management expects to see continued sequential
quarterly revenue growth through a full AXP production ramp and strong
BioArchive sales. Management also expects quarterly r
'/>"/>
| SOURCE ThermoGenesis Corp. Copyright©2008 PR Newswire. All rights reserved |